Oct. 22 at 6:48 PM
$EYPT Jay S. Duker, M.D.
4d
EyePoint has announced the closing of our underwritten public offering of
$150 million of shares of common stock, marking a significant milestone in our growth journey. This financing enables us to advance our pivotal Phase 3 program in DME, an area with significant unmet need for effective, long-lasting therapies. We are currently the only company developing a TKI for this important indication.
Thank you to everyone that contributed to this major achievement, including our investors, board of directors and employees. We’re proud to reach this milestone, and we remain committed to advancing our mission to improve the lives of patients with serious retinal diseases.
